Skip to main content
← All trials
Parkinson's DiseaseBrain and nervesDevice

What this study is

The purpose of this registry is to compile characteristics of world-wide outcomes for the use of Boston Scientific's commercially available Vercise DBS System in the treatment of Parkinson's disease.

The utilization of Image Guided Programming (IGP), and other commercially available programming features, used as planning tools for the programming of patients with Boston Scientific's Vercise DBS System are also evaluated.

Additionally, the utilization of the DBS Illumina 3D feature that may be used for the programming of patients with Boston Scientific's Vercise DBS Systems is also evaluated.

What's being tested

  • Deep Brain Stimulation (DBS)

    Intervention · DEVICE

    Subjects receiving Deep Brain Stimulation (DBS) for the treatment of their Parkinson's disease symptoms will be offered participation in this registry.

Study details

Sponsor
Boston Scientific Corporation
Conditions
Parkinson's Disease
Enrolling
1,500 people
Starts
2014-03-04
Est. completion
2038-12
Record
View on ClinicalTrials.gov ↗